Search Patents
  • Human pyruvate dehydrogenese phosphatase
    Patent number: 7250279
    Abstract: hPDP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hPDP polypeptides and polynucleotides in diagnostic assays.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: July 31, 2007
    Assignee: Merck Patent GmbH
    Inventors: Izaak Den Daas, Michael Gassen, Joachim Leibrock, Laurie Von Melchner
  • GABA-gated chloride channels
    Patent number: 7220832
    Abstract: The present invention features Dermacentor variabilis GABA-gated chloride channel polypeptides and nucleic acids, and uses of such polypeptides and nucleic acids. D. variabilis is a widely distributed tick associated with different diseases. A preferred use of the present invention is to obtain compounds for preventing or treating a tick infestation.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: May 22, 2007
    Assignee: Merck & Co., Inc
    Inventors: Yingcong Zheng, Doris F. Cully, Steve W. Ludmerer
  • Trace amine receptor 1 of the African green monkey
    Patent number: 7368541
    Abstract: A trace amine receptor 1 has been isolated from the genome of Cercopithecus aethiops (African green monkey). Described is the amino acid sequence of the receptor, the nucleic acid encoding the receptor, and methods for using the receptor to identify analytes that are agonists or antagonists of the receptor.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: May 6, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mark Eben Massari, Herve Schaffhauser, Satoshi Ozaki
  • METHOD AND AGENT FOR REFOLDING PROTEINS
    Publication number: 20100292447
    Abstract: This invention relates to the use of ionic liquids comprising a cation with at least one electron donor region and one positively charged electrostatic region which are spatially distinct from each other for protein refolding and a method for refolding proteins using said ionic liquids.
    Type: Application
    Filed: September 19, 2008
    Publication date: November 18, 2010
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: William-Robert Pitner, Jens Eichhorn, Joerg Von Hagen, Peter A. Leland, Graham B.I. Scott
  • Use of ionic liquids for membrane protein extraction
    Patent number: 8143381
    Abstract: The present invention relates to the use of ionic liquids or of mixtures comprising at least one ionic liquid and at least one further solvent for the extraction of membrane proteins from biological samples, to methods for the extraction of membrane proteins, to a kit for the extraction of these proteins and to the use thereof.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: March 27, 2012
    Assignee: Merck Patent GmbH
    Inventors: Joerg Von Hagen, Uwe Michelsen, Maria Wehsling
  • HCV RNA-dependent RNA polymerase
    Patent number: 7569374
    Abstract: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: August 4, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Donald J. Graham, Amy L. Simcoe, Steven W. Ludmerer, Osvaldo A. Flores, Robert L. LaFemina
  • PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION
    Publication number: 20110183902
    Abstract: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 28, 2011
    Applicants: Merck Sharp & Dohme Corp., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Ranabir Sinha Roy, Elisabetta Bianchi, Antonello Pessi, Paolo Ingallinella, Donald J. Marsh, George J. Eiermann, Yingjun Mu, Yun-Ping Zhou
  • P5C reductase gene from zalerion arboricloa
    Patent number: 5789222
    Abstract: There is disclosed an isolated gene coding for an enzyme involved in proline biosynthesis in Zalerion arboricola. There is also disclosed a method of using the gene to produce a strain of Z. arboricola containing high titers of a desirable fermentation product.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: August 4, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Rosemarie Kelly, Prakash S. Masurekar, Elizabeth A. Register
  • CC-chemokine binding tick proteins
    Patent number: 7635576
    Abstract: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
    Type: Grant
    Filed: December 19, 2005
    Date of Patent: December 22, 2009
    Assignee: Merck Serono SA
    Inventors: Amanda Proudfoot, Christine Power, Achim Frauenschuh
  • CC-chemokine binding tick proteins
    Patent number: 7611867
    Abstract: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: November 3, 2009
    Assignee: Merck Serono SA
    Inventors: Amanda Proudfoot, Christine Power, Maud Deruaz
  • CXC-chemokine antagonists isolated from
    Patent number: 7670802
    Abstract: A novel CXC-chemokine binding protein is cloned from the salivary glands of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immuno-modulatory compounds and in the treatment or prevention of CXC-chemokine-related diseases.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: March 2, 2010
    Assignee: Merck Serono SA
    Inventors: Amanda Proudfoot, Christine Power
  • 180 kD protein that interacts with protein histidine phosphatase 1
    Patent number: 7432348
    Abstract: 180 KDa protein histidine phosphatase interacting protein (PHPIP-180) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-180 polypeptides and polynucleotides in diagnostic assays.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: October 7, 2008
    Assignee: Merck Patent GmbH
    Inventors: Roland Kellner, Bjoern Hock
  • Human receptor tyrosine kinase, KDR
    Patent number: 6359115
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Xianzhi Mao, Kenneth A. Thomas, Andrew Tebben
  • Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
    Patent number: 5026828
    Abstract: Recombinant hepatitis B antigen bound to yeast membranes in yeast expression systems is rapidly purified by subjecting the membrane bound protein to agents that release undesired proteins, followed by agents that release the recombinant hepatitis B antigen.
    Type: Grant
    Filed: December 1, 1988
    Date of Patent: June 25, 1991
    Assignee: Merck & Co., Inc.
    Inventor: Shigeko Yamazaki
  • Purified prostaglandin receptor EP1
    Patent number: 6031079
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: February 29, 2000
    Assignees: Merck Frosst Canada, Inc., Vanderbilt University
    Inventors: Anthony Ford-Hutchinson, Richard Grygorczyk, Collin Funk, Kathleen Metters
  • Human receptor tyrosine kinase, KDR
    Patent number: 6841382
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Contraceptive vaccine
    Patent number: 5935578
    Abstract: The instant invention is drawn to a sperm surface protein in substantially pure form selected from a human PH30 beta chain protein and a mouse PH30 beta chain proteins. Such proteins are useful as contraceptive vaccines in humans and mice respectively, and for identifying small molecules that will disrupt sperm-egg interaction and fertilization.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: August 10, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth Alves, Sunil K. Gupta, Gregory Franklin Hollis
  • DNA molecules encoding human nuclear receptor protein nNR7-1
    Publication number: 20030104531
    Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding a novel member to the human nuclear receptor superfamiliy, designated nNR7 and/or nNR7-1. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of nNR7 and/or nNR7-1 activity, and production of antibodies against nNR7 and/or nNR7-1, or epitopes thereof.
    Type: Application
    Filed: March 4, 2002
    Publication date: June 5, 2003
    Applicant: Merck & co., Inc.
    Inventor: Fang Chen
  • Modified pseudomonas exotoxin PE.sub.40
    Patent number: 5621078
    Abstract: Pseudomonas exotoxin 40 is modified by deleting or substituting one or more cysteine residues. Such a modified protein, when hybridized to TGF.alpha., exhibits altered biological activities from unmodified TGF.alpha. PE.sub.40, including decreased cell killing activity and increased receptor-binding activity.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: April 15, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark W. Riemen, Steven M. Stirdivant
  • Cyclin-dependent protein kinase
    Patent number: 6030788
    Abstract: An isolated nucleic acid molecule is disclosed which encodes a novel human cyclin-dependent kinase (CDK) which comprises a novel cyclin binding domain signature sequence and lacks several heretofore conserved amino acid residues involved in regulation of the cdk/cyclin complex. Associated proteins and biologically active mutant forms are also disclosed.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: February 29, 2000
    Assignee: Merck & Co., Inc.
    Inventor: David L. Gerhold